VEGFA and age-related macular degeneration: While anti-vascular endothelial growth factor (VEGF) therapy has markedly improved outcomes for macular neovascularisation secondary to AMD, disease-specific therapy for early and non-exudative manifestations, including geographic atrophy (GA), is lacking [2, 3].